Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study

Vaccine

Volumn 32, Issue 22, 2014, Pages 2657-2665

  Harrer, Thomas ^a   Plettenberg, Andreas ^b   Arastéh, Keikawus ^c   Van Lunzen, Jan ^d   Fätkenheuer, Gerd ^e   Jaeger, Hans ^f   Janssens, Michel ^g   Burny, Wivine ^g   Collard, Alix ^g   Roman, François ^g   Loeliger, Alfred ^g   Koutsoukos, Marguerite ^g   Bourguignon, Patricia ^g   Lavreys, Ludo ^g   Voss, Gerald ^g  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

^c Vivantes Auguste Viktoria Klinikum   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f MUC Research GmbH and MVZ Karlsplatz   (Germany)

^g GSK   (Belgium)

Author keywords

AS01 adjuvant; HIV 1 infection; HIV 1 vaccine; Recombinant F4 fusion protein

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEATING; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

AS01 ADJUVANT; CD4(+) T-CELLS; HIV-1 INFECTION; HIV-1 VACCINE; RECOMBINANT F4 FUSION PROTEIN;

ADJUVANTS, IMMUNOLOGIC; ADULT; AIDS VACCINES; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; VIRAL LOAD; YOUNG ADULT;

EID: 84898540154     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.030     Document Type: Article

References (35)

1. Zhu T., Corey L., Hwangbo Y., Lee J.M., Learn G.H., Mullins J.I., et al. Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J Virol 2003, 77:6108-6116.
2. Poropatich K., Sullivan D.J. Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J Gen Virol 2011, 92:247-268.
3. + T lymphocytes. Nature 2003, 421:852-856.
4. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300:337-339.
5. Sun J.C., Williams M.A., Bevan M.J. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 2004, 5:927-933.
6. Yang T.C., Millar J., Groves T., Zhou W., Grinshtein N., Parsons R., et al. On the role of CD4+ T cells in the CD8+ T-cell response elicited by recombinant adenovirus vaccines. Mol Ther 2007, 15:997-1006.
7. Lichterfeld M., Kaufmann D.E., Yu X.G., Mui S.K., Addo M.M., Johnston M.N., et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004, 200:701-712.
8. Van Braeckel E., Bourguignon P., Koutsoukos M., Clement F., Janssens M., Carletti I., et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Infect Dis 2011, 52:522-531.
9. ClinicalTrials.gov Safety of the HIV vaccine 732461 in HIV infected subjects aged 18-55 years old 2013, Available from http://clinicaltrials.gov/ct2/show/NCT00814762 [updated 27 October 2011; accessed 24.04.13].
10. National Institute of Allergy and Infectious Diseases, Department of Health and Human Services, National Institutes for Health Division of AIDS table for grading the severity of adult and pediatric adverse events 2013, Available at http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf [updated December 2004; accessed 24.04.13].
11. Frahm N., Baker B., Brander C. Identification and optimal definition of HIV-derived cytotoxic T-lymphocyte (CTL) epitopes for the study of CTL escape, functional avidity and viral evolution. HIV molecular immunology 2008 2008, 3-24. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, New Mexico. B.T.M. Korber, C. Brander, B.F. Haynes, R. Koup, J.P. Moore, B.D. Walker, D.I. Watkins (Eds.).
12. HIV molecular immunology 2009 2009, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, New Mexico, LA-UR 09-05941. K. Yusim, B.T.M. Korber, C. Brander, B.F. Haynes, R. Koup, J.P. Moore, B.D. Walker, D.I. Watkins (Eds.).
13. Munier C.M., Andersen C.R., Kelleher A.D. HIV vaccines: progress to date. Drugs 2011, 71:387-414.
14. Girard M.P., Osmanov S., Assossou O.M., Kieny M.P. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 2011, 29:6191-6218.
15. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
16. Garçon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems. Expert Rev Vaccines 2011, 10:471-486.
17. Goepfert P.A., Tomaras G.D., Horton H., Montefiori D., Ferrari G., Deers M., et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007, 25:510-518.
18. + T-cell response in healthy adults with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 2010, 28:7016-7024.
19. Lichterfeld M., Gandhi R., Simmons R.P., Flynn T., Sbrolla A., Yu X.G., et al. Induction of strong HIV-1-specific CD4+ T cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in ARV treated HIV-1-infected individuals. J Acquir Immune Defic Syndr 2012, 59:1-9.
20. Leroux-Roels I., Forgus S., De Boever F., Clement F., Demoitié M.A., Mettens P., et al. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2013, 31:2196-2206.
21. Vandepapelière P., Horsmans Y., Moris P., Van Mechelen M., Janssens M., Koutsoukos M., et al. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008, 26:1375-1386.
22. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337-346.
23. Kannanganat S., Ibegbu C., Chennareddi L., Robinson H.L., Amara R.R. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007, 81:8468-8476.
24. Boaz M.J., Waters A., Murad S., Easterbrook P.J., Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002, 169:6376-6385.
25. Kannanganat S., Kapogiannis B.G., Ibegbu C., Chennareddi L., Goepfert P., Robinson H.L., et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 2007, 81:12071-12076.
26. Iyasere C., Tilton J.C., Johnson A.J., Younes S., Yassine-Diab B., Sekaly R.P., et al. Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol 2003, 77:10900-10909.
27. Harari A., Petitpierre S., Vallelian F., Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T-cells in HIV infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004, 103:966-972.
28. Younes S.A., Yassine-Diab B., Dumont A.R., Boulassel M.R., Grossman Z., Routy J.P., et al. HIV-1 viremia prevents the establishment of interleukin-2 producing HIV-specific memory CD4+ T-cells endowed with proliferative capacity. J Exp Med 2003, 198:1909-1922.
29. Van Braeckel E., Desombere I., Clement F., Vandekerckhove L., Verhofstede C., Vogelaers D., Leroux-Roels G. Polyfunctional CD4+ T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. Vaccine 2012, [May 21, Epub ahead of print].
30. Makedonas G., Betts M.R. Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev 2011, 239:109-124.
31. Soghoian D.Z., Streeck H. Cytolytic CD4(+) T cells in viral immunity. Expert Rev Vaccines 2010, 9:1453-1463.
32. Marshall N.B., Swain S.L. Cytotoxic CD4 T cells in anti-viral immunity. J Biomed Biotechnol 2011, 2011:954602.
33. Soghoian D.Z., Jessen H., Cutler S., Sierra-Davidson K., Cutler S., Pertel T., et al. HIV-specific cytolytic CD4 T-cell responses during acute HIV infection predict disease outcome. Sci Transl Med 2012, 4:123ra25.
34. Horowitz A., Behrens R.H., Okell L., Fooks A.R., Riley E.M. NK cells as effectors of acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following vaccination. J Immunol 2010, 185:2808-2818.
35. He X.S., Draghi M., Mahmood K., Holmes T.H., Kemble G.W., Dekker C.L., et al. T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J Clin Invest 2004, 114:1812-1819.